You can buy or sell CHRS and other stocks, options, ETFs, and crypto commission-free!
Coherus BioSciences, Inc. Common Stock, also called Coherus BioSciences, is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Read More Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar, and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
Redwood City, California
52 Week High
52 Week Low
Seeking AlphaMay 9
Coherus BioSciences, Inc. CEO Denny Lanfear on Q1 2019 Results - Earnings Call Transcript
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2019 Earnings Conference Call May 9, 2019 4:30 PM ET Company Participants David Arrington - VP, IR and Corporate Affairs Denny Lanfear - President, Chief Executive Officer and Chairman Jean Viret - Chief Financial Officer Jim Hassard - SVP, Marketing and Market Access Conference Call Participants Ken Cacciatore - Cowen and Company Chris Schott - JPMorgan Mohit Bansal - Citi Douglas Tsao - H.C. Wainwright Operator Ladies and gentlemen, thank you for stan...
Yahoo FinanceMay 9
Coherus BioSciences Reports Q1 Loss, Tops Revenue Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 36.96% and 0.73%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Expected Aug 7, After Hours